Skip to Content

Rozita Bagheri-Yarmand, Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders - Research, The University of Texas MD Anderson Cancer Center,, Houston, TX

Research Interests

Mouse model, gene targeting, oncogenes, tumor suppressors,  cell cycle, apoptosis, tyrosine kinase receptors, signal transduction, breast cancer, medulary thyroid cancer

Education & Training

Degree-Granting Education

1995 University of Paris XIII, Paris, France, PHD, Thesis with highest honors, Biochemistry and Cancer Biology
1990 University of Paris VII, Paris, France, MS, Biochemistry
1987 University of Paris VII, Paris, France, BS, Biochemistry

Postgraduate Training

1999-2002 Research Fellowship, Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
1995-1996 Postdoctoral Fellowship, Cancer Biology, French Institute of Health and Medical Research U353, Paris, France


Academic Appointments

Instructor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002-2004
Assistant Professor, Department of Cell Biology, University of Paris XIII, Paris, France, 1996-1999
Director of Core Facility, Department of Nuclear Medicine, Hospital Avicenne, Bobigny, France, 1996-1999

Institutional Committee Activities

member, Animal care and use committee, 2011-present

Honors and Awards

2012 Second place Junior Faculty poster award, Division of internal Medicine, Research Retreat, MD Anderson Cancer Center
2006 Career Development Award, University of Texas M. D. Anderson Cancer Center
1997 Distinguished Scientist Award, "Banque de la vie, Recherche Cancer" Foundation
1995 Post-doctoral Fellowship Award, Martine Midy Foundation
1991-1995 Pre-doctoral Fellowship Award, University of Paris XIII

Selected Publications

Peer-Reviewed Original Research Articles

1. Murray MM, Bui T, Smith M, Bagheri-Yarmand R, Wingate H, Hunt KK, Keyomarsi K. Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis. e-Pub 7/5/2013. PMID: 23722650.
2. Molli PR, Li DQ, Bagheri-Yarmand R, Pakala SB, Katayama H, Sen S, Iyer J, Chernoff J, Tsai MY, Nair SS, Kumar R. Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol 190(1):101-14, 7/2010. e-Pub 7/2010. PMCID: PMC2911675.
3. Bagheri-Yarmand R, Nanos-Webb A, Biernacka A, Bui T, Keyomarsi K. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. Cancer Res 70(12):5085-95, 6/2010. e-Pub 6/2010. PMCID: PMC2946214.
4. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res 70(12):5074-84, 6/2010. e-Pub 6/2010. PMCID: PMC2888821.
5. Balasenthil S, Gururaj AE, Talukder AH, Bagheri-Yarmand R, Arrington T, Haas BJ, Braisted JC, Kim I, Lee NH, Kumar R. Identification of Pax5 as a target of MTA1 in B-cell lymphomas. Cancer Res 67(15):7132-8, 8/2007. PMID: 17671180.
6. Bagheri-Yarmand R, Balasenthil S, Gururaj AE, Talukder AH, Wang YH, Lee JH, Kim YS, Zhang X, Jones DM, Medeiros LJ, Stephens LC, Liu YJ, Lee N, Kim I, Kumar R. Metastasis-associated protein 1 transgenic mice: a new model of spontaneous B-cell lymphomas. Cancer Res 67(15):7062-7, 8/2007. PMID: 17671172.
7. Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 118(11):2703-10, 6/2006. PMID: 16381000.
8. Bagheri-Yarmand R, Talukder AH, Wang RA, Vadlamudi RK, Kumar R. Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development 131(14):3469-79, 7/2004. PMID: 15226262.
9. Vadlamudi RK, Bagheri-Yarmand R, Yang Z, Balasenthil S, Nguyen D, Sahin AA, den Hollander P, Kumar R. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 5(6):575-85, 6/2004. PMID: 15193260.
10. Vadlamudi RK, Li F, Barnes CJ, Bagheri-Yarmand R, Kumar R. p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. EMBO Rep 5(2):154-60, 2/2004. PMID: 14749719.
11. Yang Z, Bagheri-Yarmand R, Balasenthil S, Hortobagyi G, Sahin AA, Barnes CJ, Kumar R. HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res 9(8):3198-203, 8/2003. PMID: 12912973.
12. Bagheri-Yarmand R, Vadlamudi RK, Kumar R. Activating transcription factor 4 overexpression inhibits proliferation and differentiation of mammary epithelium resulting in impaired lactation and accelerated involution. J Biol Chem 278(19):17421-9, 5/2003. PMID: 12611881.
13. Wang RA, Vadlamudi RK, Bagheri-Yarmand R, Beuvink I, Hynes NE, Kumar R. Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. J Cell Biol 161(3):583-92, 5/2003. PMID: 12732616.
14. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2(4):345-51, 4/2003. PMID: 12700278.
15. Talukder AH, Bagheri-Yarmand R, Williams RR, Ragoussis J, Kumar R, Raz A. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors. Clin Cancer Res 8(10):3285-9, 10/2002. PMID: 12374700.
16. Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sahin A, Hortobagyi G, Adam L, Barnes CJ, Vadlamudi RK. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418(6898):654-7, 8/2002. PMID: 12167865.
17. Bagheri-Yarmand R, Mandal M, Taludker AH, Wang RA, Vadlamudi RK, Kung HJ, Kumar R. Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J Biol Chem 276(31):29403-9, 8/2001. PMID: 11382770.
18. Bagheri-Yarmand R, Hamma-Kourbali Y, Bissieres P, Morere JF, Crepin M. Carboxymethyl benzylamide dextran and tamoxifen combination inhibits tumor growth and angiogenesis. Clin Cancer Res 7(6):1805-11, 6/2001. PMID: 11410523.
19. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK, Kumar R. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3(1):30-7, 2001. PMID: 11146623.
20. Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendelsohn J, Kumar R. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem 275(50):39451-7, 12/2000. PMID: 10967114.
21. Bagheri-Yarmand R, Kourbali Y, Rath AM, Vassy R, Martin A, Jozefonvicz J, Soria C, Lu H, Crepin M. Carboxymethyl benzylamide dextran blocks angiogenesis of MDA-MB435 breast carcinoma xenografted in fat pad and its lung metastases in nude mice. Cancer Res 59(3):507-10, 2/1999. PMID: 9973189.
22. Bagheri-Yarmand R, Kourbali Y, Mabilat C, Morere JF, Martin A, Lu H, Soria C, Jozefonvicz J, Crepin M. The suppression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumour angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7). Br J Cancer 78(1):111-8, 7/1998. PMID: 9662260.
23. Bagheri-Yarmand R, Kourbali Y, Morere JF, Jozefonvicz J, Crepin M. Inhibition of MCF-7ras tumor growth by carboxymethyl benzylamide dextran: blockage of the paracrine effect and receptor binding of transforming growth factor beta1 and platelet-derived growth factor-BB. Cell Growth Differ 9(6):497-504, 6/1998. PMID: 9663468.

Invited Articles

1. Kumar R, Wang RA, Bagheri-Yarmand R. Emerging roles of MTA family members in human cancers. Semin Oncol 30(5 Suppl 16):30-7, 10/2003. PMID: 14613024.
2. Kumar, R, Bagheri-Yarmand, R. HER2 signaling in angiogenesis. Seminars in Oncology 28:27-32, 2001.


1. Bagheri-Yarmand R, Huang SC, Cote GJ, GagelRF. Novel Mechanism of RET-mediated regulation of cell cycle progression in medullary thyroid cancer. 12th International workshop on multiple endocrine Neoplasia, 9/2010.
2. Bagheri-Yarmand R, Biernacka A, Nano-Webb A, Hunt K, Keyomarsi K. Low-Molecular-Weight Cyclin E shortens mitosis and causes chromosome missegregation through premature activation of Cdc25C. Gordon Conference, Cell Growth & Proliferation, Colby, ME, 2009.
3. Bagheri-Yarmand R, Keyomarsi K. Activatng transcription factor 4 is a novel modulator of the cell cycle through direct interaction with p27kip1. Gordon Conference. Cell Growth & Proliferation, Biddeford, ME, 2007.
4. Bagheri-Yarmand R, Kumar R. A component of the human Arp2/3 complex induces centrosome amplification, abnormal mitotic spindles and breast cancer tumorigenesis. AACR, Anaheim, 2005.
5. Bagheri-Yarmand R, Morere JF, Jozefonvicz J, Israel L, Crepin M. Dextran derivative, CMDB7 acts synergistically with tamoxifen or hydroxytamoxifen to inhibit MCF7 human breast cancer cell proliferation. ASCO, Los Angeles, 1995.
6. Bagheri-Yarmand R, Josefonvicz J, Israel L, Crepin M. Interaction of a dextran derivative (CMDB7) with autocrine growth factors in pretumoral and tumoral breast cells. IABCR, Japan, 1994.

Grant & Contract Support

Title: ATF4, a novel putative tumor suppressor gene in medullary thyroid cancer
Funding Source: American Thyroid Association
Role: Principal Investigator
Duration: 7/1/2010 - 6/30/2012

Last updated: 6/19/2014